Related Experiment Video
Updated: Aug 23, 2025

Remote Laboratory Management: Respiratory Virus Diagnostics
Published on: April 6, 2019
How can health technology assessment support our response to public health emergencies?
Aparna Ananthakrishnan1, Alia Cynthia Gonzales Luz2, Sarin Kc2
1Health Intervention and Technology Assessment Program (HITAP), Ministry of Public Health, Nonthaburi, Thailand. aparna.a@hitap.net.
Abstract:
Public health emergencies (PHEs), such as the COVID-19 crisis, are threats to global health and public order. We recommend that countries bolster their PHE responses by investing in health technology assessment (HTA), defined as a systematic process of gathering pertinent information on and evaluating health technologies from a medical, economic, social and ethical standpoint. We present examples of how HTA organizations in low- and middle-income countries have adapted to supporting PHE-related decisions during COVID-19 and describe the ways HTA can help the response to a PHE. In turn, we advocate for HTA capacity to be further developed globally and for increased institutional acceptance of these methods as a building block for preparedness and response to future PHEs. Finally, the long-term potential of HTA in strengthening health systems and embedding confidence and transparency into scientific policy should be recognized.
More Related Videos
11:38High Content Screening Analysis to Evaluate the Toxicological Effects of Harmful and Potentially Harmful Constituents HPHC
Published on: May 10, 2016
09:08Developing a Salivary Antibody Multiplex Immunoassay to Measure Human Exposure to Environmental Pathogens
Published on: September 12, 2016
Related Concept Videos
Issues And Trends In Healthcare Delivery System
Cost Containment
Payment for healthcare services has historically promoted adoption of costly and often unnecessary or inefficient...
Steps in Outbreak Investigation
Principles of Disease Surveillance
Applications of GIS: Disaster Management and Emergency Response
Current Trends in Nursing II
Hazard Ratio
For example, in a clinical trial...